Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

25d ago, source: Stockhouse

March 25, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients ...

Aerovate Therapeutics Inc AVTE

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Aerovate Therapeutics Stock (NASDAQ:AVTE), Analyst Ratings, Price Targets, Predictions

24d ago, source: Benzinga.com

Aerovate Therapeutics Inc has a consensus price target of $30.86, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from Wells Fargo, Jefferies ...

Insider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ...

29d ago, source: Yahoo Finance

Aerovate Therapeutics Inc (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that improve the treatment of severe cardiopulmonary diseases, has reported an ...

Aerovate Therapeutics Inc (AVTE) Stock: Analyzing the Market Value

10d ago, source: newsheater

In conclusion, Aerovate Therapeutics Inc (AVTE) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s ...

Aerovate Therapeutics director sells over $330k in company stock

7d ago, source: Investing

In a recent transaction, David S. Grayzel, a director at Aerovate Therapeutics, Inc. (NASDAQ:AVTE), sold a significant number of shares in the company. The transaction, which took place on April 9 ...

Aerovate Therapeutics: Poised for Market Capitalization Growth on IMPAHCT Trial Success

17d ago, source: Business Insider

Analyst Tiago Fauth of Wells Fargo maintained a Buy rating on Aerovate Therapeutics (AVTE – Research Report), retaining the price target of $35.00. Tiago Fauth’s rating is based on a thorough ...

Aerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023

22d ago, source: Yahoo Finance

Net Loss: Aerovate Therapeutics Inc (NASDAQ:AVTE) reported a net loss of $75.5 million for the year ended December 31, 2023, an increase from the previous year's $51.5 million. R&D Expenses: R&D ...

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

24d ago, source: Yahoo Finance

March 25, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of ...

Aerovate Therapeutics Inc (AVTE)

10d ago, source: Investing

In a recent move at Aerovate Therapeutics, Inc. (NASDAQ:AVTE), Chief Technical Officer Marinus (NASDAQ:MRNS) Verwijs has sold a significant amount of company stock. According to ...

Aerovate Therapeutics, Inc.: Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

24d ago, source: Finanznachrichten

March 25, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of ...